

**LOBBYING REPORT**

Lobbying Disclosure Act of 1995 (Section 5) - All Filers are Required to Complete This Page 00 AUG 11 PM 2:31

1. Registrant Name Capitol Associates, Inc.			
2. Address <input type="checkbox"/> Check if different than previously reported 426 C Street, NE, Washington, DC 20002			
3. Principal Place of Business (if different from line 2) City: _____ State/Zip (or Country): _____			
4. Contact Name Debra M. Hardy Havens	Telephone (202) 544-1880	E-mail (optional) dh@capitolassociates.com	5. Senate ID # 8101-188
7. Client Name Cell Therapeutics, Inc.	<input type="checkbox"/> Self		6. House ID # 30813018

**TYPE OF REPORT** 8. Year 2000 Midyear (January 1-June 30)  OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  ⇒ Termination Date \_\_\_\_\_ 11. No Lobbying Activity

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13	
<p align="center"><b>12. Lobbying Firms</b></p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇒ \$ <u>40,000</u> Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center"><b>13. Organizations</b></p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇒ \$ _____ Expenses (nearest \$20,000)</p> <p><b>14. REPORTING METHOD.</b> Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(c) of the Internal Revenue Code</p>

Signature Debra M. Hardy Havens  
 Printed Name and Title Debra M. Hardy Havens, CEO

Registrant Name Capitol Associates, Inc. Client Name Ceil Therapeutics, Inc.

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific lobbying issues

Funding for medical research at the NIH and drug evaluation at the FDA.

H.R. 4461- Making appropriations for Agriculture, Rural Development, Food and Drug Administration and Related Agencies programs for the fiscal year ending September 30, 2001, and for other purposes; Title VI- tracked, monitored, reported consideration of legislation.

S. 2536- An original bill making appropriations for Agriculture, Rural Development, Food and Drug Administration, and Related Agencies programs for the fiscal year ending September 30, 2001, and for other purposes; Title VI- tracked, monitored, reported consideration of legislation.

H.R. 4577- Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2001, and for other purposes; Title II- tracked, monitored, reported consideration of legislation.

S. 2553- An original bill making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September, 30, 2001, and for other purposes; Title II- tracked, monitored, reported consideration of legislation.

17. House(s) of Congress and Federal agencies contacted  Check if None

House  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Marguerite Donoghue Baxter		
Tricia Brooks		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_

Printed Name and Title Debra M. Hardy Havens, CEO

Registrant Name Capitol Associates, Inc. Client Name Cell Therapeutics, Inc.

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific lobbying issues

H.R. 1388/S. 784, Medicare Cancer Clinical Trial Coverage Act of 1999 -- tracked, monitored, reported consideration of legislation.

H.R. 2621, Pediatric Research Initiative Act of 1999 -- tracked, monitored, reported consideration of legislation.

H.R. 4605, Human Research Subjects Protections Act of 2000 -- tracked, monitored, reported consideration of legislation.

S. 1010, Medical Innovation Tax Credit for Clinical Testing Research -- tracked, monitored, reported consideration of legislation.

S. 1267, Clinical Trials Disclosure Act of 1999 -- tracked, monitored, reported consideration of legislation.

S. 1813, Clinical Research Enhancement Act of 1999 -- tracked, monitored, reported consideration of legislation.

17. House(s) of Congress and Federal agencies contacted  Check if None

House  
Senate  
Department of Health and Human Services

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Marguerite Donoghue Baxter		<input type="checkbox"/>
Tricia Brooks		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_

Printed Name and Title Debra M. Hardy Havens, CEO

Registrant Name Capitol Associates, Inc. Client Name Cell Therapeutics, Inc.

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

Tracked, monitored, and reported on prescription drug benefit legislation that affected drug pricing.  
H.R. 664/S. 731, Prescription Drug Fairness for Seniors Act  
H.R. 1885/S. 1191, International Prescription Drug Parity Act  
H.R. 2927, Affordable Prescription Drug Act  
H.R. 4680, Medicare Rx 2000 Act  
H.R. 4770, Medicare Guaranteed and Health Provider Relief Act of 2000  
S. 2464, Prescription Drug Fairness Act  
S. 2753, Medicare Expansion for Needed Drugs  
S. 2758, Medicare Outpatient Drug Act of 2000  
S. 2807, Medicare Prescription Drug and Modernization Act of 2000

17. House(s) of Congress and Federal agencies contacted  Check if None

House  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Marguerite Donoghue Baxter		
Tricia Brooks		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_

Printed Name and Title Debra M. Hardy Havens, CEO